MEMPHYS will work closely with the NHS, academia and industry to enable the rapid and widespread implementation of a host of new diagnostic and therapeutic technologies.
List view / Grid view
Steve Bremer (European Pharmaceutical Review)
Filter the results
Multiple sclerosis patients to have routine access to beta interferon drug, says NICE in new draft guidance.
With access challenges even after successful but costly development programmes, the industry is under pressure to speed up the clinical development process and produce more for less. Adaptive trial designs, more collaborative working and data sharing could provide a solution in the area of cancer immunotherapy, says Jacqueline Karmel, principal…
UCB’s ambition, according to its website, is to transform the lives of people living with severe diseases. The company’s Head of Global Clinical Development and Medical Affairs Stuart Dollow believes that making its clinical trial design more patient-centred and creating the right partnerships are key steps toward improving access to…
NPL's new approach informed by government priorities, consultancy with industry and the NHS, and a century of expertise, will see it focus on some of the world’s biggest health challenges, from supporting the diagnosis and treatment of cancer and dementia, to reducing attrition rates in drug development, to creating new…
LabCentral signs outsourced R&D provider Science Exchange, enabling access to more than 2,500 qualified scientific service providers
Puration plans to displace pharmaceutical market leader, GW Pharmaceuticals, as part of strategy to grow US cannabis market
Report predicts strong demand from biopharma will encourage NGS informatics providers to deliver customised solutions